CN117460727A - 二氢哒嗪-3,5-二酮衍生物的制造方法 - Google Patents

二氢哒嗪-3,5-二酮衍生物的制造方法 Download PDF

Info

Publication number
CN117460727A
CN117460727A CN202280041402.9A CN202280041402A CN117460727A CN 117460727 A CN117460727 A CN 117460727A CN 202280041402 A CN202280041402 A CN 202280041402A CN 117460727 A CN117460727 A CN 117460727A
Authority
CN
China
Prior art keywords
formula
powder
compound represented
solvent
ray diffraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280041402.9A
Other languages
English (en)
Chinese (zh)
Inventor
村形政利
小宫志央
侯增华
榎本太郎
谷田智嗣
福田弘志
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of CN117460727A publication Critical patent/CN117460727A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
    • B01J31/2404—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring
    • B01J31/2409—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring with more than one complexing phosphine-P atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2231/00—Catalytic reactions performed with catalysts classified in B01J31/00
    • B01J2231/40—Substitution reactions at carbon centres, e.g. C-C or C-X, i.e. carbon-hetero atom, cross-coupling, C-H activation or ring-opening reactions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/001—General concepts, e.g. reviews, relating to catalyst systems and methods of making them, the concept being defined by a common material or method/theory
    • B01J2531/002—Materials
    • B01J2531/004—Ligands
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80—Complexes comprising metals of Group VIII as the central metal
    • B01J2531/82—Metals of the platinum group
    • B01J2531/824—Palladium
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80—Complexes comprising metals of Group VIII as the central metal
    • B01J2531/84—Metals of the iron group
    • B01J2531/842—Iron
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Epidemiology (AREA)
CN202280041402.9A 2021-06-08 2022-06-08 二氢哒嗪-3,5-二酮衍生物的制造方法 Pending CN117460727A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021-096200 2021-06-08
JP2021096200 2021-06-08
PCT/JP2022/023068 WO2022260062A1 (ja) 2021-06-08 2022-06-08 ジヒドロピリダジン－３，５－ジオン誘導体の製造方法

Publications (1)

Publication Number Publication Date
CN117460727A true CN117460727A (zh) 2024-01-26

Family

ID=84426032

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280041402.9A Pending CN117460727A (zh) 2021-06-08 2022-06-08 二氢哒嗪-3,5-二酮衍生物的制造方法

Country Status (13)

Country Link
US (1) US20250115585A1 (https=)
EP (1) EP4353718A4 (https=)
JP (1) JP7665747B2 (https=)
KR (1) KR20240019168A (https=)
CN (1) CN117460727A (https=)
AR (1) AR126060A1 (https=)
AU (1) AU2022291310A1 (https=)
BR (1) BR112023023841A2 (https=)
CA (1) CA3221272A1 (https=)
IL (1) IL309054A (https=)
MX (1) MX2023013898A (https=)
TW (1) TW202313590A (https=)
WO (1) WO2022260062A1 (https=)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120322791A1 (en) * 2010-01-19 2012-12-20 Siddiqui M Arshad PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS
CN105073715A (zh) * 2013-03-13 2015-11-18 中外制药株式会社 二氢哒嗪-3,5-二酮衍生物
CN107072993A (zh) * 2014-09-12 2017-08-18 中外制药株式会社 含有钠依赖性磷酸转运蛋白抑制剂的药物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102869656B (zh) 2010-04-28 2014-03-12 安斯泰来制药株式会社 四氢苯并噻吩化合物
EP2591354B1 (en) 2010-07-07 2016-09-07 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
KR101941048B1 (ko) 2011-10-27 2019-01-22 아스텔라스세이야쿠 가부시키가이샤 아미노 알킬 치환 n-티에닐벤즈아미드 유도체
WO2014003153A1 (ja) 2012-06-28 2014-01-03 協和発酵キリン株式会社 置換アミド化合物
DE102013111551B3 (de) 2013-10-21 2015-01-22 Wago Verwaltungsgesellschaft Mbh Tragschienengehäuse
US10934280B2 (en) 2016-08-15 2021-03-02 Eli Lilly And Company Condensed thiophene derivatives useful as NaPi-IIb inhibitors
CN111801335A (zh) 2018-01-17 2020-10-20 株式会社神钢环境舒立净 亚硼酸酯化合物的合成方法、亚硼酸酯化合物的钠盐及其合成方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120322791A1 (en) * 2010-01-19 2012-12-20 Siddiqui M Arshad PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS
CN105073715A (zh) * 2013-03-13 2015-11-18 中外制药株式会社 二氢哒嗪-3,5-二酮衍生物
CN107072993A (zh) * 2014-09-12 2017-08-18 中外制药株式会社 含有钠依赖性磷酸转运蛋白抑制剂的药物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
YOSHINORI TSUBOI: "EOS789, a novel pan-phosphate transporter inhibitor, is effective for the treatment of chronic kidney disease–mineral bone disorder", KIDNEY INTERNATIONAL, vol. 98, 30 April 2020 (2020-04-30), pages 343 - 354, XP093014269, DOI: 10.1016/j.kint.2020.02.040 *
吴正红: "药剂学", 30 April 2020, 中国医药科技出版社, pages: 279 *
恽魁宏: "有机化学", 31 March 1982, 人民教育出版社, pages: 375 *

Also Published As

Publication number Publication date
EP4353718A1 (en) 2024-04-17
BR112023023841A2 (pt) 2024-01-30
JP7665747B2 (ja) 2025-04-21
EP4353718A4 (en) 2025-11-05
US20250115585A1 (en) 2025-04-10
IL309054A (en) 2024-02-01
MX2023013898A (es) 2023-12-11
WO2022260062A1 (ja) 2022-12-15
CA3221272A1 (en) 2022-12-15
AU2022291310A1 (en) 2024-01-18
JPWO2022260062A1 (https=) 2022-12-15
KR20240019168A (ko) 2024-02-14
TW202313590A (zh) 2023-04-01
AR126060A1 (es) 2023-09-06

Similar Documents

Publication Publication Date Title
JP6761448B2 (ja) アザインドールを作製するための方法および中間体
JP6514398B2 (ja) メチル｛４，６−ジアミノ−２−［１−（２−フルオロベンジル）−１Ｈ−ピラゾロ［３，４−ｂ］ピリジン−３−イル］ピリミジン−５−イル｝メチルカルバメートの調製方法および医薬上活性な化合物として用いるためのその精製方法
CN118434748A (zh) 一种六元并六元化合物、制备方法、药物组合物和应用
TW200404786A (en) Chemical process
JP7292501B2 (ja) Ｃｄ７３阻害剤の結晶形態
WO2025077663A1 (zh) 一种稠环化合物及应用
JP2008543974A (ja) ペメトレキセド二酸の結晶形およびその調製方法
JP6894917B2 (ja) ピリジニルアミノピリミジン誘導体のメシル酸塩の結晶形、その製造方法及びその使用
JP2023544775A (ja) ７－クロロ－６－フルオロ－１－（２－イソプロピル－４－メチルピリジン－３－イル）ピリド［２，３－ｄ］ピリミジン－２，４（１Ｈ，３Ｈ）－ジオンのアトロプ異性体をラセミ化及び単離するためのプロセス
CN100439336C (zh) 制备环状苯甲脒衍生物的方法
EP2870155A1 (en) Ticagrelor adducts with divalent metal salts
CN111825700A (zh) 一种吡嗪并噻唑类化合物、其应用及含其的药物组合物
CN117460727A (zh) 二氢哒嗪-3,5-二酮衍生物的制造方法
WO2003092889A1 (en) Process for the preparation of 2-aminopyrazine derivatives
JP7149980B2 (ja) ピリド［３，４－ｄ］ピリミジン誘導体又はその溶媒和物の結晶
WO2025082231A1 (zh) 一种杂芳环磺酰胺结构化合物、其药物组合物及应用
HK40103591A (zh) 二氢哒嗪-3，5-二酮衍生物的制造方法
EA052755B1 (ru) Способ получения производного дигидропиридазин-3,5-диона
EA051007B1 (ru) Способ получения производного дигидропиридазин-3,5-диона
JPH101471A (ja) Ｎ−［（キノリン−２−イル）フェニル］スルホンアミド類の結晶およびその製造方法
CN118290424A (zh) 一种基于复分解反应的氨基嘧啶并吡唑/吡咯类衍生物的制备方法
CN118164991A (zh) 一种氨基嘧啶并吡唑/吡咯类衍生物的制备方法
AU2005230922A1 (en) Crystalline forms of 5,11-dihydro-11-ethyl-5-methyl-8-{2-{(1-oxido-4-quinolinyl)oxy}ethyl}-6H-dipyrido[3,2-B:2',3'-E][1,4]diazepin-6-one
WO2024222826A1 (zh) 用于制备寡核苷酸类似物或其盐的中间体及其制备方法
HK40011691A (en) Crystal of pyrido[3, 4-d]pyrimidine derivative or solvate thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40103591

Country of ref document: HK